Cancer

Cancer is not a single disease but a family of diseases united by a common mechanism: uncontrolled cell proliferation driven by accumulated genetic and epigenetic alterations that disable the regulatory systems that normally constrain division. What makes cancer distinctive is not the identity of the cells that become cancerous — virtually any somatic cell lineage can — but the evolutionary dynamics that produce and sustain the malignant population. Cancer is cell-level natural selection operating inside a multicellular organism.

The Evolutionary Nature of Cancer

Multicellular organisms are cooperative systems in which individual cells agree, through developmental programming, to perform specialized functions and to refrain from unlimited division. Cancer cells break this agreement. They acquire mutations that activate growth-promoting pathways (oncogenes) or inactivate growth-suppressing pathways (tumor suppressor genes). Each mutation is a heritable change that confers a selective advantage on the cell lineage that carries it, allowing that lineage to outcompete its neighbors for space and resources.

This makes cancer an evolutionary process in real time. A tumor is not a static mass of identical malignant cells. It is a heterogeneous population in which subclones compete, cooperate, and evolve under selection pressures imposed by the tissue microenvironment, the immune system, and therapeutic interventions. The evolutionary framework is not merely metaphorical. Phylogenetic reconstruction of tumor cell lineages reveals branching patterns of descent, clonal expansion, and selective sweeps that mirror the patterns seen in species evolution.

Hallmarks and Enabling Characteristics

The current framework for understanding cancer biology identifies hallmarks of cancer — acquired capabilities that distinguish malignant cells from normal cells. These include: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis (the growth of blood vessels to supply the tumor), and activating invasion and metastasis. More recently, two enabling characteristics have been added: genome instability (which generates the mutations that drive selection) and inflammation (which creates a microenvironment favorable to tumor progression).

The order in which these capabilities are acquired varies between cancer types. Some cancers progress through a well-defined sequence of pre-malignant stages (colorectal cancer is the classic example: adenoma → carcinoma → metastasis). Others appear to arise suddenly, with multiple hallmarks present from the earliest detectable stage. The difference reflects the underlying mutational processes: some tissues accumulate mutations gradually over years, while others experience catastrophic chromosomal rearrangements that generate many alterations simultaneously.

Evolutionary Therapeutics

The evolutionary nature of cancer has direct therapeutic implications. Any treatment that kills cancer cells but does not eliminate all of them applies strong directional selection to the surviving population. The result is predictable: resistant subclones proliferate, and the tumor recurs. This is not a failure of treatment design in the usual sense. It is an inevitable consequence of treating an evolving population with a uniform selective pressure.

Adaptive therapy is an approach that explicitly incorporates evolutionary dynamics into treatment design. Rather than maximizing tumor cell kill at every opportunity, adaptive therapy maintains a stable tumor burden at a level that does not select strongly for resistance. The analogy is to pest management in agriculture: complete elimination is often impossible and selects for resistant strains; managed coexistence may produce better long-term outcomes. Early clinical trials of adaptive therapy in prostate cancer have shown promising results, with longer time to progression than conventional maximum-dose protocols.

Evolutionary steering extends this logic: rather than merely managing selection pressure, can we direct tumor evolution toward phenotypes that are less malignant? The concept of cost of resistance is central here. Resistant cells often pay a fitness cost in the absence of drug — they are less efficient at proliferation or more vulnerable to other stresses. Exploiting this cost through sequential or combination therapies that force the tumor to evolve in constrained directions is an active area of research.

Prevention and the Limits of Control

The evolutionary perspective on cancer also clarifies why prevention is difficult and why some cancers may be unavoidable. The mutational processes that produce cancer — DNA replication errors, oxidative damage, environmental mutagens — are byproducts of essential cellular functions. A cell cannot divide without risking replication errors. Metabolism cannot proceed without producing reactive oxygen species that damage DNA. Exposure to sunlight is necessary for vitamin D synthesis but causes ultraviolet-induced mutations in skin cells.

These are not design flaws. They are trade-offs that evolution has accepted because the benefits of cellular plasticity, metabolic activity, and environmental interaction outweigh the costs of occasional cancer. The trade-off is constitutive of multicellular life. An organism that eliminated all cancer risk would be an organism that could not heal wounds, mount immune responses, or replace damaged tissues. The question for medicine is not how to eliminate cancer but how to manage the inevitable risk intelligently: delaying onset, reducing incidence, and treating progression in ways that account for the evolutionary dynamics of the disease.